Morgan Stanley
HRTX icon

Morgan Stanley’s Heron Therapeutics HRTX Stock Holding History

Morgan Stanley’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$411K Sell
513,413
-450,438
-47% -$522K ﹤0.01% 5575
2025
Q4 		$1.25M Sell
963,851
-1,504,190
-61% -$1.86M ﹤0.01% 5069
2025
Q3 		$3.11M Sell
2,468,041
-293,550
-11% -$465K ﹤0.01% 4504
2025
Q2 		$5.72M Buy
2,761,591
+828,186
+43% +$1.69M ﹤0.01% 3951
2025
Q1 		$4.25M Sell
1,933,405
-860,785
-31% -$1.67M ﹤0.01% 4062
2024
Q4 		$4.28M Buy
2,794,190
+1,025,837
+58% +$1.66M ﹤0.01% 4128
2024
Q3 		$3.52M Buy
1,768,353
+1,000,492
+130% +$2.39M ﹤0.01% 4234
2024
Q2 		$2.69M Buy
767,861
+568,862
+286% +$1.75M ﹤0.01% 4360
2024
Q1 		$551K Sell
198,999
-725,297
-78% -$1.82M ﹤0.01% 5273
2023
Q4 		$1.57M Buy
924,296
+488,789
+112% +$538K ﹤0.01% 5067
2023
Q3 		$449K Buy
435,507
+58,237
+15% +$82.9K ﹤0.01% 5221
2023
Q2 		$438K Sell
377,270
-78,727
-17% -$140K ﹤0.01% 5286
2023
Q1 		$689K Sell
455,997
-355,904
-44% -$891K ﹤0.01% 5069
2022
Q4 		$2.03M Sell
811,901
-134,412
-14% -$433K ﹤0.01% 4452
2022
Q3 		$3.99M Sell
946,313
-1,091,582
-54% -$4.27M ﹤0.01% 3881
2022
Q2 		$5.68M Buy
2,037,895
+567,067
+39% +$2.28M ﹤0.01% 3647
2022
Q1 		$8.41M Buy
1,470,828
+1,178,629
+403% +$8.62M ﹤0.01% 3115
2021
Q4 		$2.67M Sell
292,199
-72,570
-20% -$741K ﹤0.01% 4343
2021
Q3 		$3.9M Sell
364,769
-155,629
-30% -$1.89M ﹤0.01% 3982
2021
Q2 		$8.08M Sell
520,398
-98,330
-16% -$1.56M ﹤0.01% 3246
2021
Q1 		$10M Buy
618,728
+158,965
+35% +$2.83M ﹤0.01% 2648
2020
Q4 		$9.73M Buy
459,763
+271,879
+145% +$4.73M ﹤0.01% 2532
2020
Q3 		$2.78M Buy
187,884
+96,089
+105% +$1.5M ﹤0.01% 3341
2020
Q2 		$1.35M Sell
91,795
-429,386
-82% -$7.05M ﹤0.01% 3934
2020
Q1 		$6.12M Buy
521,181
+325,758
+167% +$6.12M ﹤0.01% 2257
2019
Q4 		$4.59M Buy
195,423
+127,508
+188% +$2.82M ﹤0.01% 3288
2019
Q3 		$1.26M Buy
67,915
+29,977
+79% +$552K ﹤0.01% 4152
2019
Q2 		$705K Sell
37,938
-26,308
-41% -$526K ﹤0.01% 4427
2019
Q1 		$1.57M Sell
64,246
-365,531
-85% -$9.57M ﹤0.01% 3785
2018
Q4 		$11.1M Buy
429,777
+262,171
+156% +$7.21M ﹤0.01% 2017
2018
Q3 		$5.3M Sell
167,606
-196,396
-54% -$7.31M ﹤0.01% 3132
2018
Q2 		$14.1M Buy
364,002
+213,862
+142% +$6.81M ﹤0.01% 1996
2018
Q1 		$4.14M Buy
150,140
+11,464
+8% +$260K ﹤0.01% 3218
2017
Q4 		$2.51M Buy
138,676
+66,633
+92% +$1.09M ﹤0.01% 3831
2017
Q3 		$1.16M Sell
72,043
-29,030
-29% -$455K ﹤0.01% 4330
2017
Q2 		$1.4M Buy
101,073
+1,040
+1% +$15.1K ﹤0.01% 4109
2017
Q1 		$1.5M Sell
100,033
-56,840
-36% -$787K ﹤0.01% 4055
2016
Q4 		$2.05M Buy
156,873
+72,859
+87% +$1.14M ﹤0.01% 3906
2016
Q3 		$1.45M Buy
84,014
+61,210
+268% +$1.14M ﹤0.01% 3751
2016
Q2 		$411K Buy
22,804
+13,546
+146% +$264K ﹤0.01% 4542
2016
Q1 		$175K Sell
9,258
-42,915
-82% -$847K ﹤0.01% 5053
2015
Q4 		$1.39M Sell
52,173
-26,324
-34% -$704K ﹤0.01% 3798
2015
Q3 		$1.92M Sell
78,497
-150,465
-66% -$5.01M ﹤0.01% 3554
2015
Q2 		$7.13M Sell
228,962
-59,840
-21% -$1.13M ﹤0.01% 2455
2015
Q1 		$4.2M Buy
288,802
+267,192
+1,236% +$3.01M ﹤0.01% 2910
2014
Q4 		$217K Buy
21,610
+17,872
+478% +$146K ﹤0.01% 5196
2014
Q3 		$32K Sell
3,738
-3,107
-45% -$28.9K ﹤0.01% 5861
2014
Q2 		$84K Sell
6,845
-109,916
-94% -$1.31M ﹤0.01% 5571
2014
Q1 		$1.62M Buy
+116,761
New +$1.56M ﹤0.01% 3608

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Morgan Stanley's HRTX Position: Q1 2026 in Review

Morgan Stanley reduced its Heron Therapeutics (HRTX) stake by 47% in Q1 2026, selling an estimated $522K and leaving 513,413 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #5575.

Morgan Stanley first reported a position in HRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $14.1M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Morgan Stanley held 513,413 shares of Heron Therapeutics worth $411K as of Q1 2026.
  • Morgan Stanley sold 450,438 Heron Therapeutics shares in Q1 2026, an estimated $522K.
  • Heron Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5575 holding.
  • Morgan Stanley first reported a position in Heron Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Morgan Stanley's Heron Therapeutics position peaked at $14.1M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.